<code id='29051FC327'></code><style id='29051FC327'></style>
    • <acronym id='29051FC327'></acronym>
      <center id='29051FC327'><center id='29051FC327'><tfoot id='29051FC327'></tfoot></center><abbr id='29051FC327'><dir id='29051FC327'><tfoot id='29051FC327'></tfoot><noframes id='29051FC327'>

    • <optgroup id='29051FC327'><strike id='29051FC327'><sup id='29051FC327'></sup></strike><code id='29051FC327'></code></optgroup>
        1. <b id='29051FC327'><label id='29051FC327'><select id='29051FC327'><dt id='29051FC327'><span id='29051FC327'></span></dt></select></label></b><u id='29051FC327'></u>
          <i id='29051FC327'><strike id='29051FC327'><tt id='29051FC327'><pre id='29051FC327'></pre></tt></strike></i>

          knowledge

          knowledge

          author:hotspot    Page View:51
          Smartphone & medicine illustration
          Alex Hogan/STAT

          Pear Therapeutics may be gone, but one of its most important deals is still driving critical conversations about how medical apps can find a foothold in the slow-moving health care system.

          In recent months, representatives of the Massachusetts state Medicaid program, MassHealth, have been presenting data suggesting reSET and reSET-O, Pear’s prescription apps that treat substance use disorder and opioid use disorder, saved the state money over a one-year period from 2021 to 2022. The data, which take into account health care utilization before and after people used the apps, have been presented to policymakers considering how to cover novel digital health products and shown to lawmakers considering federal legislation that would require Medicare coverage for prescription apps.

          advertisement

          Pear, which filed for bankruptcy earlier this year, was one of the leading companies marketing prescription digital therapeutics, or Food and Drug Administration-cleared apps designed to treat disease. Pear’s reSET was the first such app cleared by the FDA in 2017.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          MD Anderson's Padmanee Sharma responds to research credit suit
          MD Anderson's Padmanee Sharma responds to research credit suit

          Photoillustration:STAT;Photo:AdobeProminentimmunologistandoncologistPadmaneeSharmadefendedherselfinc

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          A deep dive into Applied Therapeutics’ data, and questions on Cassava

          MollyFerguson/STATHaveyouheardthenews?I’mlaunchingaweeklyemailnewsletterstartingonMarch28.It’scalled